Fu et al. also reported a dual-drug PEGylated nanoliposome formulation (ARNIPL) that co-encapsulates ARV-825, a BRD4-targeting PROTAC, and nintedanib, a tumor stroma-modulating agent, aiming to enhance therapeutic efficacy against vemurafenib-resistant melanoma (Figure 7) [107]. Here, BRD4 is linked to neoplasm.